More tools:Markets·Screener·Research·Chat

Omeros Corporation (OMER) Financial Statements

Omeros Corporation
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001SPJH21
XNAS · usd
19.39▲ 0.27 (1.41%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales—
EV / Revenue—
EV / EBITDA
Financial Highlights
Revenue (TTM)—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close19.12
Day's Range18.93 – 19.55
52-Week Range3.94 – 19.65
Volume1.5M
Avg Volume2.0M
Share Statistics
Shares Outstanding
Employees175
ExchangeXNAS
Listed2009-10-08
Share count as of August 7, 2026
Loading Income Statement…
Key questions about Omeros Corporation (OMER)
What is Omeros Corporation's Market Cap?
Omeros Corporation's Market Cap is $1.4B, based on as-reported figures from SEC (XBRL) filings.
What is Omeros Corporation's Enterprise Value?
Omeros Corporation's Enterprise Value is $1.3B, based on as-reported figures from SEC (XBRL) filings.
What is Omeros Corporation's Trailing P/E?
Omeros Corporation's Trailing P/E is 11.2×, based on as-reported figures from SEC (XBRL) filings.
What is Omeros Corporation's EV / EBITDA?
Omeros Corporation's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Omeros Corporation's Net Income (TTM)?
Omeros Corporation's Net Income (TTM) is $124.8M, based on as-reported figures from SEC (XBRL) filings.
What is Omeros Corporation's EBITDA?
Omeros Corporation's EBITDA is -$71.9M, based on as-reported figures from SEC (XBRL) filings.
What is Omeros Corporation's Diluted EPS (TTM)?
Omeros Corporation's Diluted EPS (TTM) is 1.72, based on as-reported figures from SEC (XBRL) filings.
What is Omeros Corporation's Net Debt?
Omeros Corporation's Net Debt is -$58.7M, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Product sales, net——
YoY growth————
Costs and expenses:
Cost of product sales——
Research and development
Selling, general and administrative
Total costs and expenses
% of revenue99.7%276.1%——
Income (loss) from operations
% of revenue0.3%-176.1%——
Interest and other income
Interest expense, net of remeasurement adjustments and other
Net gain on change in fair value of financial instruments
Loss on early extinguishment of Notes——
Income (loss) from continuing operations before income tax expense——
Income tax expense——
Net income (loss) from continuing operations
Net income (loss)
% of revenue46.4%566.7%——
Net income from discontinued operations (in dollars per share)
Net income (loss) (in dollars per share)